Tasly Holding Group
VC Fund
Tianjin, China
Tasly Holding Group is a VC fund in Tianjin focused on Health Care and Medical. Incorporated in 1994, Tasly Holding Group has now developed to an internationalized and high-tech cooperation, engaging in pan-health industry with biological medicine industry as the core business, health industry and medical service as two supporting businesses.Guided by Chinese ancient civilization, Tasly is devoted to the philosophy “seekingfor harmonization between human and nature, improving humankind life quality” . With the mission of “to share the joy of health with all”, Tasly aims to become the No. 1 in modern biological pharmaceuticals and leader of integrated health industry in China. By now, Tasly has set up a pan-health industry line, which contains six core industries，including bio-pharmaceutical industry, health products industry, herbs industry, medical industry, health management industry and children education industry.Aiming to realize TCM globalization, Tasly has been sticking to develop the international market since its foundation. By now, more than 30 types of preparation products in 8 medical categories of Tasly have been put into the international market. And the export routes cover 23 countries in America, Europe, Africa and Asia. With the distribution network spreading to more than 40 countries, Tasly’s distributor members have almost reached a million in the world. In recent years, Tasly has been listed in the top 10 of TCM exporters in China. And in 2016, Tasly Pharm. Co.,Ltd was listed in the Top 500 of Chinese Enterprises released by the US Fortune magazine.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries Tasly Holding Group invests in
Stages Tasly Holding Group invests in
Countries Tasly Holding Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $3.8M–$14M
- Series B
- $2.8M–$56M
Investment Focus
Industry
- Health Care 9 (47%)
- Medical 7 (37%)
- Biotechnology 4 (21%)
- Pharmaceutical 4 (21%)
- Medical Device 3 (16%)
Stage
- Series A 6 (32%)
- Angel 2 (11%)
- Series B 2 (11%)
- Series D 2 (11%)
- Seed 1 (5%)
Country
- China 14 (74%)
- Canada 1 (5%)
- Hong Kong 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Yan XiJun
Founder & President
|
Founder & President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tokyo Lifestyle
|
Tokyo Lifestyle is a import and retail of Japanese beauty and cosmetic products and operates live e-commerce business. | $2.8M / Debt Financing / Jul 10, 2024 | |
Hegea Bio
|
Hegeia Biotechnology is a company that focused on the research and development of siRNA, tiny nucleic acid attached delivery medicines. | $13.8M / Series A / Mar 28, 2024 | |
Hengyu Medical
|
Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment. | Series D / Mar 22, 2024 | |
Yuanyi Biotech
|
Yuanyi Biotech is specialized in creating artificial microbial technology and products. It designs and builds new gene metabolic pathways using "engineering" thinking and effective gene editing tools, creating cell factories with extremely high productivity, and offering one-stop solutions for integrated strain development, fermentationprocess optimization, industrial fermentation production, and product development. | $13.7M / Series A / Oct 18, 2023 | |
|
Hengyu Medical
|
Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment. | $14.2M / Series C / Jul 18, 2023 | |
|
Hengyu Medical
|
Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment. | Series C / Jan 07, 2022 | |
Micot
|
Micot is a new molecular entity drug developer for peptides, dedicated to the development of innovative drugs, multi- and protein-based innovative biopharmaceuticals, vaccines and biomolecular drug delivery systems and products, and for drug screening and biopharmaceutical research. The technology combines to provide users with Bio-Res-Deliv, abiological macromolecular respiratory drug delivery system, suitable for the treatment of cardiovascular diseases, metabolic diseases, liver diseases and the like. | $55.5M / Series B / Jun 22, 2021 | |
Global Health Ark Medical Technology
|
Global Health Ark Medical Technology is a high-tech company that combines university research and industrial production. | $7.7M / Series A / May 06, 2021 | |
Avicanna
|
Avicanna is a biotechnology company that focuses on the medical cannabis industry. It provides the global marketplace with advanced natural cannabinoid solutions through an evidence-based approach offered across several product platforms including API, medical, pharmaceutical, and derma cosmetic. As a multinational organization with verticalintegration, Avicanna is focused on utilizing the scientific research related to plant-derived cannabinoid products through its internal research platforms and strategic collaborations with world-class research institutions.Avicanna was founded in 2016 and is headquartered in Toronto, Ontario, CA. | Post-IPO Equity / Apr 21, 2020 | |
Zhangshang Tangyi
|
Zhangshang Tangyi is a health management platform with a focus on diabetes. It allows patients to upload their own health data to their mobile app and receive treatment guidance from doctors. Zhangshang Tangyi was founded in 2014 and is based in Hangzhou, Zhejiang. | $144M / Series D / Jan 08, 2020 | |
| See all 19 investments → | |||
Co-Investors
Northern Light Venture Capital
2 deals together
Alibaba Group
1 deal together
BVCF
1 deal together
BioVenture
1 deal together
Bojiang Capital
1 deal together
China Traditional Chinese Medicine Holdings
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Tasly Holding Group invest in?
Tasly Holding Group invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Angel stage. Most of the 19 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Tasly Holding Group's check size?
Tasly Holding Group typically joins rounds of $3.8M–$14M at Series A and $2.8M–$56M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tasly Holding Group participates in.
How do I contact Tasly Holding Group?
Public channels for Tasly Holding Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tasly Holding Group?
The team at Tasly Holding Group includes Yan XiJun (Founder & President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
